Adaptive Platform Treatment Trial for Outpatients with COVID-19 - ACTIV-2

Site Image

Study Overview

The ACTIV-2 Study is testing an investigational medicine to see if they are safe and can help adults with COVID-19 get better.
The type of investigational medicine you might receive in the study is a monoclonal antibody. Antibodies are naturally made by your body to help fight disease. Monoclonal antibodies are made in the laboratory and help your body attack invaders, such as viruses, to keep them from entering your cells. 

We also want to see if this study drug is safe, can stop the disease process and prevent hospitalization. 

If you decide to join, you would be given information about the medicines currently being tested.

Study Description

The study lasts about 6 months. You will have in-person visits to check on the status of your health. Most of these visits will happen during the first month of the study. You will also have phone calls or video chats from your home with a researcher. 

Additional Information:

To find out more information please visit: 
https://www.riseabovecovid.org/en/ 

  • Study Identifier: 843864

Recruitment Status

Open

Check to see if you pre-qualify for the study.

Are you 18 years old or older?
Back
Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu